Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Siegel on the Need for Durable Remissions in Patients With Multiple Myeloma

July 23rd 2024

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

July 19th 2024

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

July 19th 2024

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

July 18th 2024

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

July 18th 2024

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

Dr Biran on the IMROZ Trial in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 17th 2024

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

July 17th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

Dr Biran on the DREAMM-7 Trial in Multiple Myeloma

July 11th 2024

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Dr Garfall on Long-Term Data for Teclistamab in Relapsed/Refractory Myeloma

July 11th 2024

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Dr Krishnan on Patient Characteristics Associated With Early Relapse in Multiple Myeloma

July 11th 2024

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

July 9th 2024

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

July 9th 2024

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

Dr Biran on Future Research Directions in Multiple Myeloma

July 8th 2024

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma

July 2nd 2024

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy

July 2nd 2024

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

Improving CAR T-Cell Therapy in Multiple Myeloma

July 2nd 2024

Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.

Belantamab Mafodotin–Based Combo Boosts PFS in Difficult-to-Treat R/R Myeloma Subgroups

July 1st 2024

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

June 28th 2024

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma

June 27th 2024

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies

June 27th 2024

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.